Patents by Inventor Lloyd J. Old

Lloyd J. Old has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SEROMIC ANALYSIS OF OVARIAN CANCER
    Publication number: 20120283115
    Abstract: The invention relates to the discovery of cancer antigens associated with ovarian cancer. In further aspects, the invention relates to methods, compositions and kits for the diagnosis and treatment of cancer, particularly ovarian and pancreatic cancers.
    Type: Application
    Filed: August 30, 2010
    Publication date: November 8, 2012
    Applicant: Ludwig Institute for Cancer Research Ltd.
    Inventors: Gerd Ritter, Lloyd J. Old, Constance Old, Sacha Gnjatic, Kunle Odunsi, Dirk Jager
  • METHOD FOR INDUCING CELL LYSIS WITH IMMUNOGENIC PORTIONS OF NY-ESO-1 PROTEIN
    Publication number: 20120231035
    Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
    Type: Application
    Filed: February 24, 2012
    Publication date: September 13, 2012
    Inventors: Alexander Knuth, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Ali Gure, Gerd Ritter, Lloyd J. Old, Jan W. Drijfhout
  • Human sarcoma-associated antigens
    Patent number: 8252903
    Abstract: The invention relates to sarcoma-associated antigens and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof associated with sarcoma in methods and compositions for the diagnosis and treatment of diseases, such as cancer. More specifically, the invention relates to the discovery of a novel cancer/testis (CT) antigen, NY-SAR-35.
    Type: Grant
    Filed: January 6, 2010
    Date of Patent: August 28, 2012
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Matthew J. Scanlan, Cynthia H. Scanlan, legal representative, Sang-Yull Lee, Lloyd J. Old
  • SPECIFIC BINDING PROTEINS AND USES THEREOF
    Publication number: 20120183471
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: February 17, 2010
    Publication date: July 19, 2012
    Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH
    Inventors: Lloyd J. Old, Constance Old, Andrew Mark Scott, Gerd Ritter, Achim Jungbluth, Elisabeth Stockert, Stephen Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice, Anne Murray, George Mark, Terrance Grant Johns, Con Panousis, Christoph Renner
  • Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein
    Patent number: 8142786
    Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: March 27, 2012
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Alexander Knuth, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Ali Gure, Gerd Ritter, Lloyd J. Old, Jan W. Drijfhout
  • SPECIFIC BINDING PROTEINS AND USES THEREOF
    Publication number: 20110313230
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: April 1, 2011
    Publication date: December 22, 2011
    Inventors: Terrance Grant Johns, Andrew Mark Scott, Gerd Ritter, Achim Jungbluth, Elizabeth Stockert, Stephen Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice, Anne Murray, George Mark, Lloyd J. Old, Edward B. Reilly, Andrew C. Phillips, Jonathan A. Meulbroek, Fritz G. Buchanan
  • SPECIFIC BINDING PROTEINS AND USES THEREOF
    Publication number: 20110293511
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: April 1, 2011
    Publication date: December 1, 2011
    Inventors: Terrance Grant Johns, Andrew Mark Scott, Gerd Ritter, Achim Jungbluth, Elizabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice, Anne Murray, George Mark, Lloyd J. Old, Edward B. Reilly, Andrew C. Phillips, Jonathan A. Meulbroek, Fritz G. Buchanan, Stephen Stockert
  • Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein
    Publication number: 20110182944
    Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
    Type: Application
    Filed: January 10, 2011
    Publication date: July 28, 2011
    Inventors: Alexander Knuth, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Ali Gure, Gerd Ritter, Lloyd J. Old, Jan W. Drijfhout
  • Cancer-testis antigens
    Publication number: 20110177079
    Abstract: The invention relates to cancer-testis antigens and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof in methods and compositions for the diagnosis and treatment of diseases, such as cancer. More specifically, the invention relates to the discovery of novel cancer-testis (CT) antigens.
    Type: Application
    Filed: September 8, 2005
    Publication date: July 21, 2011
    Applicants: Ludwig Institute for Cancer Research, Cornell Research Foundation, Inc.
    Inventors: Yao-Tseng Chen, Lloyd J. Old, Andrew J.G. Simpson, Victor C. Jongeneel, Matthew J. Scanlan, Cynthia H. Scanlan
  • Colon Cancer Associated Transcript 1 (CCAT1) As A Cancer Marker
    Publication number: 20110097271
    Abstract: The present invention relates to the identification, isolation, and sequencing of a unique nucleic acid transcript termed Colon Cancer Associated Transcript 1 (CCAT-1) that is specifically expressed in cancer cells, in particular in colon, rectal, and lung cancer, as well as in precancerous lesions. The present invention thus provides methods for diagnosing cancer by detecting the expression of CCAT-1 as well as isolated polynucleotides, compositions and kits for use in the detection methods of the invention.
    Type: Application
    Filed: February 11, 2009
    Publication date: April 28, 2011
    Applicants: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LI, LUDWIG INSTITUTE FOR CANCER RESEARCH AND CANCER IN
    Inventors: Aviram Nissan, Stella Mitrani-Rosenbaum, Herbert Rudolf Freund, Tamar Peretz-Yablonsky, Marina Roistacher, Lloyd J. Old, Gerd Ritter, Ali O. Gure
  • SPECIFIC BINDING PROTEINS AND USES THEREOF
    Publication number: 20110076232
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: September 24, 2010
    Publication date: March 31, 2011
    Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH
    Inventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew Mark Scott, Christoph Renner, Achim Jungbluth, Elizabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice, Anne Murray, George Mark, Gerd Ritter
  • Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein
    Patent number: 7888100
    Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: February 15, 2011
    Assignees: Memorial Sloan-Kettering Cancer Research, Ludwig Institute for Cancer Research, Cornell Research Foundation, Inc.
    Inventors: Alexander Knuth, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Ali Gure, Gerd Ritter, Lloyd J. Old, Jan W. Drijfhout
  • EGF receptor epitope peptides and uses thereof
    Publication number: 20100322937
    Abstract: The present invention relates generally to growth factor receptor epitope peptides, particularly EGF family receptor epitope peptides. The invention also relates to the use of the receptor peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against the receptor peptides. Methods for generating an immune response and for treatment of tumors and cancer are also provided.
    Type: Application
    Filed: January 29, 2010
    Publication date: December 23, 2010
    Inventors: Terrance Grant Johns, Andrew Mark Scott, Antony Wilks Burgess, Lloyd J. Old, Timothy E. Adams, K. Dane Wittrup, Ginger Chao, Peter Anthony Hoyne
  • Method for inducing immune response to NY-CO-58
    Patent number: 7803382
    Abstract: The invention provides methods, compositions and kits for inducing and/or enhancing an immune response in a subject. The invention in some aspects includes polypeptide and nucleic acid molecules that induce and/or enhance an immune response. In some aspects of the invention, the polypeptide and/or nucleic acid molecules of the invention are useful to induce and/or enhance an immune response in a subject who has or is suspected of having cancer.
    Type: Grant
    Filed: September 9, 2004
    Date of Patent: September 28, 2010
    Assignees: Ludwig Institute for Cancer Research Ltd., Chancelors Masters and Scholars of the University of Oxford
    Inventors: Lloyd J. Old, Sacha Gnjatic, Djordje Atanackovic, Vincenzo Cerundolo, Khoon-Lin Ling
  • Antibodies to EGF receptor epitope peptides
    Patent number: 7767792
    Abstract: The present invention relates generally to growth factor receptor epitope peptides, particularly EGF family receptor epitope peptides. The invention also relates to the use of the receptor peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against the receptor peptides. Methods for generating an immune response and for treatment of tumors and cancer are also provided.
    Type: Grant
    Filed: February 17, 2005
    Date of Patent: August 3, 2010
    Assignees: Ludwig Institute for Cancer Research Ltd., Commonwealth Scientific & Industrial Research Organization, Massachusetts Institute for Technology
    Inventors: Terrance Grant Johns, Andrew Mark Scott, Antony Wilks Burgess, Lloyd J. Old, Timothy E. Adams, K. Dane Wittrup, Ginger Chao, Peter Anthony Hoyne
  • HUMAN SARCOMA-ASSOCIATED ANTIGENS
    Publication number: 20100172910
    Abstract: The invention relates to sarcoma-associated antigens and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof associated with sarcoma in methods and compositions for the diagnosis and treatment of diseases, such as cancer. More specifically, the invention relates to the discovery of a novel cancer/testis (CT) antigen, NY-SAR-35.
    Type: Application
    Filed: January 6, 2010
    Publication date: July 8, 2010
    Applicant: Ludwig Institute for Cancer Research Ltd.
    Inventors: Matthew J. Scanlan, Cynthia H. Scanlan, Sang-Yull Lee, Lloyd J. Old
  • SPECIFIC BINDING PROTEINS AND USES THEREOF
    Publication number: 20100056762
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: February 18, 2009
    Publication date: March 4, 2010
    Inventor: Lloyd J. Old
  • Human sarcoma-associated antigens
    Patent number: 7662917
    Abstract: The invention relates to sarcoma-associated antigens and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof associated with sarcoma in methods and compositions for the diagnosis and treatment of diseases, such as cancer. More specifically, the invention relates to the discovery of a novel cancer/testis (CT) antigen, NY-SAR-35.
    Type: Grant
    Filed: September 30, 2003
    Date of Patent: February 16, 2010
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Matthew J. Scanlan, Cynthia H. Scanlan, legal representative, Sang-Yull Lee, Lloyd J. Old
  • Methods for Stimulating an Immune Response Using Bacterial Antigen Delivery System
    Publication number: 20090324651
    Abstract: The invention relates to the use of the type III secretion system of bacteria to stimulate immune responses against tumor antigen(s) for treating antigen-loss variant tumors. Methods are provided for stimulating and/or increasing an immune response against tumor antigens. The invention also relates to the preparation of antigen presenting cells from peripheral blood mononuclear cells using bacteria having a type III secretion system.
    Type: Application
    Filed: October 3, 2006
    Publication date: December 31, 2009
    Inventors: Lloyd J. Old, Gerd Ritter, Hiroyoshi Nishikawa, Sacha Gnjatic, Jorge E. Galan
  • Specific binding proteins and uses thereof
    Patent number: 7589180
    Abstract: The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.
    Type: Grant
    Filed: May 13, 2002
    Date of Patent: September 15, 2009
    Assignee: Abbott Laboratories Inc.
    Inventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew Mark Scott, Christoph Renner, Gerd Ritter, Achim Jungbluth, Elisabeth Stockert, Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice